Alnylam Pharma has been riding high since revealing top-line results from its HELIOS-B trial of vutrisiran in transthyretin-mediated amyloidosis (ATTR) – but a look at the full data seems to ...

Vutrisiran is the generic name for AMVUTTRA, which is currently approved by the U.S. FDA for the treatment of the polyneuropathy of hereditary ATTR amyloidosis in adults. As part of the submission ...

Alnylam is riding high today after reporting its RNAi drug vutrisiran showed across-the-board efficacy in cardiomyopathy associated with transthyretin-mediated amyloidosis (ATTR), setting up ...

Alnylam Pharmaceuticals has strong growth potential, particularly with Amvuttra for ATTR-CM. Read why ALNY stock justifies a ...

In a report released yesterday, Whitney Ijem from Canaccord Genuity maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), ...

Vutrisiran MarketThe global vutrisiran market, valued at USD 600 million in 2022, is expected to experience substantial growth, reaching an estimated USD 2,087 million by 2033, with a compound annual ...

Vutrisiran is the generic name for AMVUTTRA ®, which is currently approved in the European Union (EU) for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients ...

(RTTNews) - Alnylam Pharmaceuticals (ALNY) announced the submission of a Type II Variation to the European Medicines Agency for vutrisiran, an investigational RNAi therapeutic in development for ...

Alnylam Pharmaceuticals ALNY announced that it has submitted a Type II Variation to the European Medicines Agency for vutrisiran, an investigational RNAi therapeutic being developed to treat ATTR ...

− Type II Variation Submission Based on the Positive HELIOS-B Phase 3 Study in which Vutrisiran Significantly Reduced the Risk of Death and Cardiovascular Events Relative to Placebo – "Today ...